Targeted screening

Targeted screening has been studied in 7 papers since 2025: 2 observational studies in people, 4 reviews; 6 in the past year. The newest paper, Oct 11, 2026: “Osteoporosis in men, an underdiagnosed condition: risk factors, diagnosis, and management of fragility fractures”.

Exposure

7 papers study it5 findingsUpdated

1 new paper in 30 daysSee all 7 papers on targeted screening

At a glance

The findings reach people, from one lab or study. 3 independent labs in 2 countries.

“Established cut-off values for pTau217 reflecting amyloid pathology showed pathological levels in 10-23% of participants depending on single or double cut-offs.”
Enhancing Alzheimer's disease diagnosis in primary care through targeted screening of people at risk of developing dementia - study design and feasibility assessment of the PREDEM primary care studyAlzheimer's research & therapy2026doi:10.1186/s13195-026-02162-w

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 3 independent labs in 2 countries
  • Funders: Karolinska Institutet and 4 more
  • 2 of 4 findings with company ties
  • Humans2
  • In silico1

What did studies of targeted screening find?

2

Studies of targeted screening measured 2 outcomes: Cost-effectiveness and Budgetary sustainability.

Cost-effectiveness

upin humans1upin silico1

2 studies
  1. Targeted screening improves cost-effectiveness in silico (decision-tree model using community-based prevalence data) (Rs 7729; US$23 per additional detected AF case).

    In silicodecision-tree model using community-based prevalence data1 year

  2. Targeted screening improves cost-effectiveness in humans (compared with universal screening).

    Reviewcompared with universal screening

Budgetary sustainability

upin humans1

1 study
  1. Targeted screening improves budgetary sustainability in humans.

    Reviewtargeting high-risk subgroups using nonmydriatic digital fundus photography and artificial intelligence tools

What is targeted screening linked with?

2

Studies link targeted screening with 2 measures: detectable cognitive impairment and pathological pTau217 levels.

Detectable cognitive impairment

upin humans1

1 study
  1. Targeted screening is associated with detectable cognitive impairment in humans (hypertension or type 2 diabetes and self-reported memory complaints) (approximately one-third).

    Humanshypertension or type 2 diabetes and self-reported memory complaintsn = 40

Pathological pTau217 levels

upin humans1

1 study
  1. Targeted screening is associated with pathological pTau217 levels in humans (hypertension or type 2 diabetes and self-reported memory complaints) (10-23%).

    Humanshypertension or type 2 diabetes and self-reported memory complaintsn = 40

More on Pathological pTau217 levels

Funding

2 grants since 2020

National Institute for Health Research£587KProstate Cancer Foundation

Contains public sector information licensed under the Open Government Licence v3.0.

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 2Oct 2026: 2Nov 2026: 06 papers in 12 months